Quantum Genomics extends its collaboration agreement with its partner in animal health (AcT)

Companies to continue joint development of therapies to treat heart failure in dogs
 

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has extended its collaboration agreement with its partner, a world leader in animal health.

Under this agreement, the two companies will continue working together to initiate additional clinical trials of the drug candidate developed by Quantum Genomics for the treatment of heart failure in dogs. The specific financial terms of the contact remain undisclosed.

Lionel Segard, Quantum Genomics' President and Chief Executive Officer, commented:

“The goal of this partnership is to overcome heart failure challenges in dogs. We are pleased to extend our collaboration with a major player in the industry and continue the evaluation of veterinary applications for our unique therapeutic candidates. We believe such collaborative veterinary clinical development efforts will further strengthen our position in the field of heart failure, at a time when we are launching our Phase IIa trial in humans.”